Stock listing

NYSE:MANE Veradermics, Incorporated Stock

Home listing (NYSE) of Veradermics, Incorporated

Follow Veradermics, Incorporated into a list and get an email when it puts out news.

Share price · NYSE:MANE

$119.52 USD -5.34 (-4.3%)

Close on Nov 20, 2026

Since Feb 4, 2026 +216.6% · daily closes, Feb 4, 2026 – Nov 20, 2026, adjusted for splits
Day range
$118.99 – $123.70 USDNov 20, 2026
Volume
374,921 sharesNov 20, 2026
Market cap
$5.04B USDAt the close on Nov 20, 2026 · price × 42.20M shares outstanding
Traded on an average day
$88.38M USDMedian day 623,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Veradermics, Incorporated logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:MANE · Home$119.52 USD-5.34 (-4.3%)374,921$121.98$123.70$118.99$124.86Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:MANE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$119.52-5.34-4.3%$121.98$123.70$118.99374,921
$124.86-0.78-0.6%$127.60$127.68$122.98265,259
$125.64-2.41-1.9%$128.00$129.81$124.48400,801
$128.05-1.61-1.2%$131.66$131.94$127.32487,646
$129.66-5.63-4.2%$134.06$136.97$128.24937,783
$135.29-21.27-13.6%$146.66$147.54$133.922,305,377
$156.56+8.12+5.5%$148.74$156.60$146.81697,760
$148.44+4.49+3.1%$141.81$152.82$141.81599,209
$143.95+5.17+3.7%$138.06$145.47$131.39491,919
$138.78+10.18+7.9%$130.93$139.89$130.00500,253
$128.60-7.91-5.8%$136.20$136.50$125.40788,054
$136.51+2.90+2.2%$136.51$138.66$130.51561,949
$133.61+4.08+3.1%$131.02$138.48$131.02536,271
$129.53-10.16-7.3%$139.00$139.72$128.94635,534
$139.69-4.16-2.9%$141.79$145.41$138.33464,764
$143.85+0.020.0%$141.96$146.58$140.19513,422
$143.83+3.11+2.2%$139.17$144.26$137.68397,213
$140.72+3.33+2.4%$136.84$141.08$136.76466,648
$137.39-1.39-1.0%$136.74$140.80$136.67392,381
$138.78+0.29+0.2%$139.44$139.93$134.49423,100
$138.49+1.83+1.3%$136.00$141.75$135.14794,100
$136.66+9.55+7.5%$127.50$139.12$127.14706,900
$127.11+4.83+3.9%$120.62$130.11$113.521,068,700
$122.28+13.46+12.4%$115.34$123.93$113.001,463,900
$108.82-6.25-5.4%$114.19$114.25$106.51672,900
$115.07+1.60+1.4%$112.74$115.99$111.05688,900
$113.47-2.79-2.4%$115.35$118.91$112.62484,600
$116.26-6.14-5.0%$121.17$122.27$115.67845,100
$122.40-8.50-6.5%$129.99$129.99$120.57991,400
$130.90+4.27+3.4%$125.71$135.12$123.021,113,900
$126.63+15.68+14.1%$111.60$136.72$110.563,489,900
$110.95+1.99+1.8%$108.92$113.43$108.84655,100
$108.96-9.91-8.3%$119.29$119.29$108.77736,723
$118.87+2.11+1.8%$116.45$119.12$114.80536,363
$116.76-0.46-0.4%$120.26$120.85$115.48598,300
$117.22-4.01-3.3%$121.23$123.83$116.04659,800
$121.23+3.41+2.9%$117.56$122.44$116.76689,400
$117.82+2.82+2.5%$115.34$118.94$112.03481,700
$115.00-1.57-1.3%$114.57$118.00$112.30633,500
$116.57+0.85+0.7%$116.00$118.15$113.88613,600
$115.72-0.06-0.1%$115.29$117.91$111.51580,700
$115.78-2.36-2.0%$118.11$118.74$110.60753,800
$118.14+5.34+4.7%$113.99$122.00$113.222,135,900
$112.80+6.05+5.7%$107.44$113.24$105.40583,600
$106.75-1.93-1.8%$109.30$109.30$104.541,870,200
$108.68+6.26+6.1%$105.56$109.74$102.83766,500
$102.42-1.47-1.4%$103.86$104.93$100.50860,200
$103.89+2.19+2.2%$102.02$105.26$100.01938,800
$101.70+2.73+2.8%$99.31$104.19$98.46620,700
$98.97+0.83+0.8%$99.45$102.29$98.82576,000
$98.14-1.53-1.5%$98.96$99.86$97.04394,400
$99.67-4.16-4.0%$103.20$104.53$97.00552,600
$103.83+5.32+5.4%$99.00$104.23$98.17712,800
$98.51+0.76+0.8%$98.92$99.89$97.20363,000
$97.75-0.71-0.7%$99.74$100.98$95.42356,200
$98.46+0.95+1.0%$97.80$100.55$95.44427,200
$97.51-0.90-0.9%$98.59$100.86$97.27548,300
$98.41+0.48+0.5%$100.00$101.38$97.14678,500
$97.93-3.88-3.8%$102.30$102.41$97.00623,500
$101.81-0.99-1.0%$102.06$103.44$100.39270,800
$102.80+0.45+0.4%$102.04$104.87$101.30657,000
$102.35+3.89+4.0%$100.31$104.08$97.73787,163
$98.46-4.36-4.2%$100.00$102.75$93.81717,278
$102.82-2.50-2.4%$105.18$108.87$102.52393,600
$105.32-5.91-5.3%$111.00$111.39$101.69773,100
Ticker
NYSE:MANE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE
Currency
USD

What changed lately

Latest news

All Veradermics, Incorporated news

Veradermics, Incorporated on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 25 in all · newest Nov 12, 2026 · oldest 2026
Decks
7 decks · latest Nov 9, 2026

Where Veradermics, Incorporated is listed

ListingExchangeCountryCurrency
NYSE:MANE · Home listing · This pageNYSEUnited StatesUSD
BX Swiss:MANEBX SwissSwitzerlandCHF
BOATS:MANEBOATSUnited StatesUSD

Valuation

Price/book 6.3× against a median of 6.6×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$4.25B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
6.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.13

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Veradermics, Incorporated · NYSE:MANEUS$5.04BUS$4.25Bn/an/an/a6.3×n/a0.0×1.13
Belite Bio, Inc. · NASDAQ:BLTEUS$5.13BUS$5.13Bn/an/an/a6.6×n/a0.0×1.34
SK Biopharmaceuticals Co., Ltd. · KRX:326030US$5.08BUS$4.80B16.9×7.5×20.1×6.7×46.6%0.0×n/a
Liquidia Corporation · NASDAQ:LQDAUS$4.90BUS$4.68Bn/a7.5×n/an/a−15.2%n/a0.84
Erasca, Inc. · NASDAQ:ERASUS$4.78BUS$4.18Bn/an/an/a5.2×n/a0.1×1.51
Dianthus Therapeutics, Inc. · NASDAQ:DNTHUS$4.76BUS$3.92Bn/a1,444×n/a3.8×n/a0.0×0.90
PTC Therapeutics, Inc. · NASDAQ:PTCTUS$4.71BUS$3.12Bn/a2.7×n/an/a−9.2%n/a0.88
Cogent Biosciences, Inc. · NASDAQ:COGTUS$4.65BUS$4.08Bn/an/an/a9.0×n/a0.4×1.30
Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSAUS$4.53BUS$3.97B41.4×4.2×29.9×6.4×11.6%0.0×0.57
Travere Therapeutics, Inc. · NASDAQ:TVTXUS$4.51BUS$4.21Bn/a6.5×n/a200×−18.7%0.0×1.31
Ionis Pharmaceuticals, Inc. · NASDAQ:IONSUS$4.43BUS$4.70Bn/a4.9×n/a11.3×−56.9%5.5×0.40
Median of the othersUS$4.74BUS$4.19B29.2×6.5×25.0×6.6×−12.2%0.0×0.90

Forecasts

6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
178.17 USD · Analysts' mean
EPS, year to Dec 2026
-2.87 · 6 analysts

Team and board

Officers

OfficerRole
Reid WaldmanChief Executive Officer and Board Member
Dominic CarranoChief Financial Officer and Treasurer
Michael GrecoGeneral Counsel
David A. HollanderChief R&D Officer
Mark NeumannChief Commercial and Strategy Officer
Tim DursoChief Technical Officer

Board

DirectorRole
John W. ChildsChairman
David FriedmanBoard Member
Jane Grant-KelsBoard Member
Katarina PanceBoard Member
Patrick EnrightBoard Member
Reid WaldmanChief Executive Officer and Board Member
Vlad CoricBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close+5.5%
Q2 2026Aug 11, 2026 · After close+0.1%
Q1 2026May 15, 2026 · After close+0.7%
Q4 2025Mar 30, 2026 · After close+3.8%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update54 slidesNov 9, 2026
Corporate Update (October 2026)Corporate update50 slidesOct 19, 2026
Investor Presentation (September 2026)Investor deck69 slidesSeptember 2026
Technical Presentation (July 2026)Technical41 slidesJul 15, 2026
Technical Presentation (July 2026)Technical41 slidesJuly 2026
Technical Presentation (April 2026)Technical39 slidesApr 27, 2026
Technical Presentation (April 2026)Technical39 slidesApril 2026

Open Decks

Financings

RaiseDate
Public offering of common stock
Made bigger: about US$384.4M · US$100 a share · Jefferies +6
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Citigroup (co-lead), Cantor (co-lead), LifeSci, Needham & Company, LifeSci Capital
Apr 30, 2026
Private placement of pre-funded warrants
Update: about US$30M · US$100 a share · Jefferies +5
Dealers: Jefferies, Leerink Partners, Citigroup, Cantor, LifeSci Capital, Needham & Company
Buyers: Suvretta Capital (certain affiliated entities buying 300,000 pre-funded warrants)
Apr 30, 2026
Public offering of common stock
Closed: US$294.8M raised · US$17 a share · Jefferies +3
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Citigroup (co-lead), Cantor (co-lead)
Feb 5, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Feb 3, 2026.

Price
US$17.00 a share
Shares offered
15,077,647 shares of common stock
Offering size
US$256.3 million
Underwriters' option
Up to 2,261,647 more shares
Listing
MANE on the New York Stock Exchange
Underwriters
Jefferies, Leerink Partners, Citigroup, Cantor · In the order on the cover
Shares delivered
On or about Feb 5, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceOct 27, 2025
Filed publiclyJan 9, 2026
Amended onceJan 28, 2026
Declared effective by the SECJan 30, 2026
Shares registered with an exchangeFeb 3, 2026
Final prospectus, with the priceFeb 4, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Feb 4, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue000
Research and development62.1M23.3M15.0M
Selling, general and administrative10.3M3.50M2.35M
Operating income-72.3M-26.8M-17.3M
Interest expense0585.0K36.0K
Income before tax-70.0M-26.5M-16.5M
Income tax00
Net income-70.0M-26.5M-16.5M
Earnings per share, basic-111.91-37.05-0.08
Earnings per share, diluted-111.91-37.05

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents21.8M53.1M16.3M
Short-term investments120.1M0
Receivables1.25M1.38M
Current assets152.5M55.5M17.6M
Property, plant and equipment22.0K0
Total assets152.6M55.5M18.5M
Accounts payable2.13M2.25M1.85M
Current liabilities9.15M4.72M3.05M
Long-term debt786.0K
Total debt4.00K786.0K
Total liabilities9.16M4.72M3.84M
Shareholders' equity-121.0M-48.5M14.6M
Shares outstanding749.8K736.9K201.3M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-71.6M-23.7M-13.5M
Capital spending-24.0K00
Free cash flow-71.6M-23.7M-13.5M
Cash from investing-118.9M0
Cash from financing159.1M60.5M13.9M
Change in cash-31.3M36.8M385.0K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13D/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
8-K · Current reportNov 9, 2026Current reportSEC
8-K · Current reportOct 19, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 13, 2026Big-stake noticeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
All 104 filings
FilingDateTypeFiled with
SCHEDULE 13D/A · Big-stake notice, amendedAug 21, 2026Big-stake noticeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 20, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 17, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
144/A · Notice of proposed sale, amendedAug 14, 2026Other filingsSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
424B3 · ProspectusAug 14, 2026Offer documentSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
S-1 · Registration statementAug 7, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
8-K · Current reportJul 15, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
DMay 15, 2026Other filingsSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMay 7, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 5, 2026Big-stake noticeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 5, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeMay 5, 2026Big-stake noticeSEC
3 · Initial statement of ownershipMay 5, 2026Insider tradeSEC
8-K · Current reportMay 1, 2026Material contractSEC
424B4 · ProspectusApr 30, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 30, 2026Other filingsSEC
FWP · Free writing prospectusApr 29, 2026Offer documentSEC
S-1MEF · Registration of more shares for the same offeringApr 29, 2026Offer documentSEC
FWP · Free writing prospectusApr 27, 2026Offer documentSEC
CORRESP · Letter to the SECApr 27, 2026Other filingsSEC
CORRESP · Letter to the SECApr 27, 2026Other filingsSEC
S-1 · Registration statementApr 27, 2026Offer documentSEC
8-K · Current reportApr 27, 2026ResultsSEC
8-K · Current reportApr 27, 2026Current reportSEC
UPLOAD · Letter from the SECApr 7, 2026Other filingsSEC
DRS · Draft registration statementApr 6, 2026Offer documentSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 30, 2026ResultsSEC
4/A · Change in ownership, amendedFeb 27, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 5, 2026Offer documentSEC
8-K · Current reportFeb 5, 2026Current reportSEC
424B4 · ProspectusFeb 4, 2026Offer documentSEC
CERT · Exchange's certificate of listingFeb 4, 2026Other filingsSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringFeb 3, 2026Offer documentSEC
8-A12B · Registration of shares for listing on an exchangeFeb 3, 2026Other filingsSEC
FWP · Free writing prospectusFeb 2, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
S-1/A · Registration statement, amendedJan 28, 2026Offer documentSEC
S-1 · Registration statementJan 9, 2026Offer documentSEC
DOct 28, 2025Other filingsSEC
DRS · Draft registration statementOct 24, 2025Offer documentSEC
DDec 10, 2024Other filingsSEC
DMay 1, 2023Other filingsSEC
D/AOct 7, 2021Other filingsSEC
DOct 6, 2021Other filingsSEC
DOct 9, 2020Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Veradermics, Incorporated’s releases · as of Nov 5, 2026

Common shares
42,195,472
Fully diluted
42,195,472

Fully diluted

LineSharesAs of
Common shares42,195,472Nov 5, 2026

Share count over time

CountShares
Nov 5, 202642,195,472

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Montanova Capital, LLC3.72M8.8%US$451MSep 30, 2026
Fidelity3.06M7.3%US$371MSep 30, 2026
JPMorgan2.37M5.6%US$280MSep 30, 2026
Sr One Capital Management, LP2.08M4.9%US$252MSep 30, 2026
Citadel2.05M4.9%US$248MSep 30, 2026
BlackRock1.93M4.6%US$234MSep 30, 2026
Deep Track Capital, LP1.9M4.5%US$230MSep 30, 2026
Vanguard1.59M3.8%US$193MSep 30, 2026
Siren, L.L.C.1.32M3.1%US$161MSep 30, 2026
D. E. Shaw & Co., Inc.1.27M3.0%US$154MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Adage Capital Partners Gp, L.L.C.1.07M2.5%US$130MSep 30, 2026
abrdn992K2.4%US$120MSep 30, 2026
Maverick Capital LTD942K2.2%US$114MSep 30, 2026
Infinitum Asset Management, LLC833K2.0%US$101MSep 30, 2026
Jennison Associates LLC816K1.9%US$98.9MSep 30, 2026
Holocene Advisors, LP706K1.7%US$85.6MSep 30, 2026
State Street636K1.5%US$77.1MSep 30, 2026
Geode Capital622K1.5%US$75.5MSep 30, 2026
UBS597K1.4%US$72.4MSep 30, 2026
Woodline Partners LP502K1.2%US$60.8MSep 30, 2026
BNY364K0.86%US$44.1MSep 30, 2026
Emerald Advisers, LLC332K0.79%US$40.3MSep 30, 2026
Paradigm Biocapital Advisors LP310K0.73%US$37.6MSep 30, 2026
Gilder Gagnon Howe & Co LLC307K0.73%US$37.2MSep 30, 2026
Ameriprise290K0.69%US$35.1MSep 30, 2026
Ensign Peak Advisors, Inc276K0.65%US$33.4MSep 30, 2026
Schwab257K0.61%US$31.2MSep 30, 2026
Emerald Mutual Fund Advisers Trust226K0.53%US$27.3MSep 30, 2026
Bamco Inc220K0.52%US$26.6MSep 30, 2026
Northern Trust210K0.50%US$25.5MSep 30, 2026
Alyeska Investment Group, L.P.199K0.47%US$24.1MSep 30, 2026
Stifel Financial Corp194K0.46%US$23.5MSep 30, 2026
Marshall Wace, LLP186K0.44%US$22.5MSep 30, 2026
Logos Global Management LP170K0.40%US$20.6MSep 30, 2026
Renaissance Technologies149K0.35%US$18.1MSep 30, 2026
Kalehua Capital Management LLC146K0.35%US$17.7MSep 30, 2026
Sun Life145K0.34%US$17.6MSep 30, 2026
Sofinnova Investments, Inc.144K0.34%US$17.5MSep 30, 2026
First Turn Management, LLC137K0.32%US$16.6MSep 30, 2026
Wilshire Advisors LLC134K0.32%US$16.3MSep 30, 2026
Seven Grand Managers, LLC125K0.30%US$15.2MSep 30, 2026
Goldman Sachs122K0.29%US$14.8MSep 30, 2026
Franklin Templeton112K0.27%US$15.3MSep 30, 2026
Longaeva Partners L.P.110K0.26%US$13.3MSep 30, 2026
Masters Capital Management LLC100K0.24%US$12.1MSep 30, 2026
Perceptive Advisors LLC97,0000.23%US$11.8MSep 30, 2026
Catalio Capital Management, LP95,6460.23%US$11.6MSep 30, 2026
Frontier Capital Management Co LLC92,1740.22%US$11.2MSep 30, 2026
BNP Paribas87,8580.21%US$10.7MSep 30, 2026
Wellington83,3490.20%US$10.1MSep 30, 2026

This page holds 50 of 201 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Growth Company Fund746K1.8%US$75.2MMay 31, 2026
Vanguard Total Stock Market Index Fund618K1.5%US$76MJun 30, 2026
iShares Russell 2000 ETF536K1.3%US$65.9MJun 30, 2026
JPMorgan Growth Advantage Fund321K0.76%US$39.4MJun 30, 2026
JPMorgan Small Cap Growth Fund264K0.63%US$32.4MJun 30, 2026
Fidelity Small Cap Index Fund238K0.56%US$25MJul 31, 2026
Vanguard Extended Market Index Fund231K0.55%US$28.4MJun 30, 2026
Fidelity Growth Company K6 Fund210K0.50%US$21.1MMay 31, 2026
Fidelity Worldwide Fund208K0.49%US$21.8MJul 31, 2026
Fidelity Series Growth Company Fund188K0.45%US$19MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Select Health Care Portfolio180K0.43%US$18.2MMay 31, 2026
iShares Russell 2000 Growth ETF134K0.32%US$16.5MJun 30, 2026
PGIM Jennison Health Sciences Fund128K0.30%US$12.9MMay 29, 2026
Baron Discovery Fund126K0.30%US$15.5MJun 30, 2026
MFS New Discovery Fund108K0.26%US$10.9MMay 31, 2026
Fidelity Extended Market Index Fund102K0.24%US$10.3MMay 31, 2026
Emerald Growth Fund101K0.24%US$10.6MJul 31, 2026
Emerald Growth Fund101K0.24%US$10MApr 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund100K0.24%US$10.1MMay 31, 2026
Schwab U.S. Small-Cap ETF94,6350.22%US$9.55MMay 31, 2026
Fidelity U.S. Equity Central Fund87,5000.21%US$10.8MJun 30, 2026
PGIM Jennison Small Company Fund86,8150.21%US$10.7MJun 30, 2026
SmallCap Growth Fund I85,9100.20%US$9.02MJul 31, 2026
JPMorgan Small Cap Blend Fund83,8640.20%US$10.3MJun 30, 2026
JPMorgan Active Growth ETF71,5610.17%US$8.8MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF70,3100.17%US$8.64MJun 30, 2026
iShares Russell 2000 Value ETF60,0370.14%US$7.38MJun 30, 2026
Fidelity Advisor Health Care Fund60,0000.14%US$6.3MJul 31, 2026
First Trust US Equity Opportunities ETF53,8730.13%US$6.62MJun 30, 2026
Schwab Small-Cap Index Fund52,8730.13%US$5.55MJul 31, 2026
iShares U.S. Pharmaceuticals ETF52,0650.12%US$6.4MJun 30, 2026
Fidelity Contrafund49,1540.12%US$6.04MJun 30, 2026
VIP Health Care Portfolio42,0000.10%US$5.16MJun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund41,8170.10%US$4.22MMay 31, 2026
MFS New Discovery Series39,2250.09%US$4.82MJun 30, 2026
Master Small Cap Index Series38,7090.09%US$4.76MJun 30, 2026
BNY Mellon Small/Mid Cap Growth Fund38,2610.09%US$4.7MJun 30, 2026
Fidelity Total Market Index Fund37,3340.09%US$3.77MMay 31, 2026
F/m Emerald Life Sciences Innovation ETF35,5680.08%US$3.59MMay 31, 2026
Franklin Biotechnology Discovery Fund31,0810.07%US$3.26MJul 31, 2026
Fidelity Series Total Market Index Fund30,2640.07%US$3.05MMay 31, 2026
Twin Oak Strategic Solutions ETF30,0000.07%US$3.03MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF28,5380.07%US$3.51MJun 30, 2026
Nuveen Small Cap Blend Index Fund27,8190.07%US$2.92MJul 31, 2026
JNL Multi-Manager Small Cap Growth Fund26,2760.06%US$3.23MJun 30, 2026
LVIP Baron Growth Opportunities Fund24,7600.06%US$3.04MJun 30, 2026
EQ/2000 Managed Volatility Portfolio22,4720.05%US$2.76MJun 30, 2026
Select Biotechnology Portfolio20,8000.05%US$2.1MMay 31, 2026
VIP Stock Selector Portfolio18,4000.04%US$2.26MJun 30, 2026
Blackstone Alternative Multi-Strategy Fund18,2240.04%US$2.24MJun 30, 2026

This page holds 50 of 152 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Longitude Capital Partners V, LLC
10% owner
Sale250,000USD 150.38US$37.6MNov 11, 2026
Longitude Capital Partners V, LLC
10% owner
Sale250,000USD 150.38US$37.6MNov 11, 2026
Patrick G. Enright
Director
Sale250,000USD 150.38US$37.6MNov 11, 2026
Patrick G. Enright
Director
Sale250,000USD 150.38US$37.6MNov 11, 2026
Averill Master Fund, Ltd.
Director
Sale690,601USD 107.25US$74.1MAug 19, 2026
Averill Master Fund, Ltd.
Director
Sale59,399USD 107.25US$6.37MAug 19, 2026
Waldman Reid Alexander
Director, Officer: Chief Executive Officer
Sale11,527USD 106.72US$1.23MAug 17, 2026
Waldman Reid Alexander
Director, Officer: Chief Executive Officer
Sale25,234USD 107.53US$2.71MAug 17, 2026
Waldman Reid Alexander
Director, Officer: Chief Executive Officer
Sale27,490USD 108.45US$2.98MAug 17, 2026
Waldman Reid Alexander
Director, Officer: Chief Executive Officer
Sale3,000USD 109.38US$328KAug 17, 2026
All 19 trades
TradeTradeSharesPriceValueDate
Waldman Reid Alexander
Director, Officer: Chief Executive Officer
Sale249USD 111.28US$27,709Aug 17, 2026
Durso Timothy August
Officer: Chief Technical Officer
Sale7,918USD 106.71US$845KAug 17, 2026
Durso Timothy August
Officer: Chief Technical Officer
Sale16,306USD 107.52US$1.75MAug 17, 2026
Durso Timothy August
Officer: Chief Technical Officer
Sale16,767USD 108.38US$1.82MAug 17, 2026
Durso Timothy August
Officer: Chief Technical Officer
Sale2,348USD 109.34US$257KAug 17, 2026
Durso Timothy August
Officer: Chief Technical Officer
Sale161USD 111.28US$17,916Aug 17, 2026
Childs John W
Director
Sale15,000USD 106.14US$1.59MAug 12, 2026
Childs John W
Director
Sale80,000USD 107.23US$8.58MAug 12, 2026
Childs John W
Director
Sale5,000USD 108.24US$541KAug 12, 2026

Big stakes

StakeStakeSharesDateFiling
Patrick G. Enright9.80%4.15MNov 11, 2026Schedule 13D
Montanova Capital, LLC8.80%3.72MAug 19, 2026Schedule 13D
FMR LLC7.60%3.19MJun 30, 2026Schedule 13G
JPMorgan Chase & Co5.60%2.37MSep 30, 2026Schedule 13G
SR One Capital Management, LLC4.90%2.08MAug 12, 2026Schedule 13D
Seven Fleet Capital Management LP0.20%80,000May 1, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Vlad Coric
Other companies: Royalty Pharma plc (Director · Since at least Apr 7, 2025); Biohaven Ltd. (Chairman & Chief Executive Officer · Since at least Sep 22, 2022); Revance Therapeutics, Inc. (Director · Mar 1, 2023 – Feb 4, 2025 · Past); Akili Inc (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Biohaven Pharmaceutical Holding Co Ltd (Chief Executive Officer, Director · May 3, 2017 – Oct 3, 2022 · Past)
Board Member · Since at least Feb 3, 2026
John W. Childs
Other companies: Biohaven Ltd. (Director · Since at least Sep 28, 2022); Biohaven Pharmaceutical Holding Co Ltd (Director · Mar 22, 2019 – Oct 3, 2022 · Past)
Chairman · Since at least Feb 3, 2026
Aaron Cowen
Other companies: Benitec Biopharma Inc. (Director · Since at least Sep 26, 2024)
Director · Since at least Feb 4, 2026
David Friedman
Other companies: Benitec Biopharma Inc. (Director · Since at least Mar 25, 2025)
Board Member · Since at least Nov 5, 2026
Mark Neumann
Other companies: Intra-Cellular Therapies Inc (EVP, Chief Commercial Officer · Oct 15, 2018 – Apr 2, 2025 · Past)
Chief Commercial Officer · Since at least Feb 3, 2026
Patrick G. Enright
Other companies: Jazz Pharmaceuticals plc (Managing Director, Longitude Capital · Since at least Aug 5, 2026)
Board Member · Since at least Nov 5, 2026
Reid Waldman
Other companies: Achieve Life Sciences, Inc. (Director · Since at least May 29, 2026)
Chief Executive Officer and Board Member · Since at least Feb 3, 2026
David A. HollanderChief R&D Officer · Since at least Sep 1, 2026
Dominic CarranoChief Financial Officer and Treasurer · Since at least Nov 4, 2026
Jane Grant-KelsBoard Member · Since at least Feb 3, 2026
All 14 people
PersonSeat
Katarina PanceBoard Member · Since at least Feb 3, 2026
Mark NeumannChief Commercial and Strategy Officer · Since at least Mar 30, 2026
Michael GrecoGeneral Counsel · Since at least Nov 4, 2026
Tim DursoChief Technical Officer · Since at least Aug 18, 2026

Open People

Log in to ask 6ix AI your own questions about Veradermics, Incorporated.